Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Lipo-CSmall moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: MIC injection, lipotropic injection, Lipo-C MIC
Thirty-seven randomized controlled trials on L-carnitine alone. Zero on the Lipo-C combination itself. That gap tells you exactly where this product sits in 2026. Lipo-C is a compounded injection containing six ingredients (Methionine, Inositol, Choline, L-Carnitine, Thiamine, Dexpanthenol) that each play a documented role in hepatic fat processing. Weight loss clinics pair it with GLP-1 agonists like semaglutide to offset energy deficits during aggressive caloric restriction. Community reports consistently confirm the energy boost from B vitamins. Fat loss without a caloric deficit? Both the research and thousands of user reports agree: that doesn't happen.
Lipo-C (also called lipotropic MIC injection) is a compounded blend of Methionine 15 mg, Inositol 50 mg, Choline Chloride 50 mg, L-Carnitine 50 mg, Thiamine 15 mg, and Dexpanthenol 5 mg per mL. It's not FDA-approved and not a single compound. It's a pharmacy-mixed cocktail of amino acids and B vitamins designed for metabolic support during caloric restriction. The individual components have real mechanistic backing. L-carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation. A 2025 umbrella meta-analysis covering 16,352 participants across 8 meta-analyses [1] confirmed L-carnitine significantly reduces body weight (effect size -1.11 kg, p=0.005) and waist circumference (-1.34 cm, p<0.001). Choline is required for phosphatidylcholine synthesis and VLDL-mediated fat export from the liver; a 2025 RCT of 79 patients supports its role in hepatic steatosis. The problem is that nobody has tested these six ingredients together in a controlled trial. All evidence is component-level. Weight loss clinics (Defy Medical, Empower, Fella Health) routinely prescribe Lipo-C alongside semaglutide or tirzepatide. Community experience across hundreds of reports on ExcelMale and r/peptides is consistent: energy improves within hours. Fat loss without a caloric deficit does not. Lipo-C is best understood as metabolic support, not a primary intervention. The formulation arrives pre-mixed and requires no reconstitution, which lowers the barrier compared to lyophilized peptides. Standard dosing is 1 mL injected intramuscularly or subcutaneously, two to three times per week.
Six ingredients, six distinct metabolic contributions. Methionine donates methyl groups required for hepatic fat processing and is a precursor to S-adenosylmethionine (SAMe), which drives phospholipid synthesis. Inositol is a secondary messenger in insulin signaling pathways and assists in redistributing body fat away from the liver. Choline is the rate-limiting nutrient for phosphatidylcholine production. Phosphatidylcholine is the primary phospholipid in VLDL particles, the liver's main vehicle for exporting triglycerides. Without adequate choline, fat accumulates in hepatic tissue. That connection is well established in nutritional biochemistry. L-Carnitine handles the transport step. It shuttles long-chain fatty acids across the inner mitochondrial membrane through the carnitine palmitoyltransferase (CPT) system, enabling beta-oxidation. The 2025 umbrella meta-analysis [1] confirmed this translates to measurable, if modest, reductions in body weight and waist circumference across 16,352 pooled participants. Thiamine (vitamin B1) and Dexpanthenol (provitamin B5) function as cofactors in the citric acid cycle and downstream energy metabolism pathways. Their contribution explains the 2 to 4 hour energy spike that users consistently report after injection. These are water-soluble vitamins; excess is excreted renally rather than stored. The combined mechanism is additive rather than complementary. Each component acts through a separate pathway. No evidence supports any emergent property of the blend beyond what the individual ingredients provide separately.
No RCTs exist for the Lipo-C blend as a whole. Individual components have varying evidence: L-carnitine meta-analyses (2024–2025, n=16,352+) show modest but statistically significant weight/BMI reduction; a 2025 RCT (n=79) supports choline/phosphatidylcholine for hepatic steatosis; inositol has moderate evidence in PCOS. Combined injectable efficacy is unproven.
Umbrella meta-analysis 2025 (PMID 40298161): L-carnitine significantly reduces body weight (ES −1.11, p=0.005), BMI (−0.33, p=0.026), waist circumference (−1.34, p<0.001) across 8 meta-analyses, 16,352 participants. High heterogeneity (I²~90%): effect is real but modest.
Zero RCTs evaluate the Lipo-C combination formula specifically. All evidence is component-level. No large-scale RCT exists for IM/SC lipotropic MIC injections in humans. High heterogeneity limits generalizability of L-carnitine meta-analyses.
Broadly used as a metabolic support adjunct in clinical weight loss programs, especially alongside GLP-1 agonists. Energy boost from B-vitamins is the most consistently reported benefit. Fat loss without caloric deficit: near-zero consensus benefit.
Both science and community agree: Lipo-C is at best a supportive adjunct requiring a caloric deficit and exercise to produce fat loss. Science confirms component-level mechanisms; community confirms energy benefit but not standalone fat loss. No meaningful divergence in primary conclusion.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mL | 2x/week |
| Moderate | 1mL | 3x/week |
| Aggressive | 1mL | Daily |
Lipo-C arrives pre-mixed from the compounding pharmacy. No reconstitution math, no bacteriostatic water, no insulin syringe unit conversions. Draw 1 mL from the vial and inject. That's the whole protocol. One thing most beginners miss: "Lipo-C" is not a standardized product. Empower Pharmacy ships a 4-ingredient formula. Hallandale sends a 10-ingredient version they call "Bio Boost Plus" that includes lidocaine, L-arginine, B6, and B12. Both get labeled Lipo-C. Confirm your exact formulation with your prescriber before comparing notes with anyone else's protocol. Keep the vial refrigerated at 2 to 8 degrees C. If you see white precipitate (crystallization from cold storage), warm the vial to room temperature and gently roll it. Don't shake. If particulates don't clear after warming, don't inject that vial. Standard 30 mL vial at 1 mL per injection gives you 30 doses. At 2x/week, that's 15 weeks from one vial, which stretches past the typical 12-week course. Check pharmacy dating; most are labeled for 90-day use after compounding.
Cycling is recommended to allow the body to recalibrate baseline nutrient levels. Many clinics run 12-week courses with a short break before resuming. No receptor desensitization is expected since these are nutrients, not receptor agonists.
Lipo-C components are nutrients (amino acids, vitamins), not receptor agonists: no receptor desensitization occurs. Cycling is recommended to allow metabolic recalibration, assess ongoing need, provide a break from injection site burden, and monitor for cumulative effects (e.g., hypermethioninemia in susceptible individuals). Standard clinic protocol: 12 weeks on, 2 weeks off before resuming.
Or use the universal Peptide Calculator for any peptide.
Expected: Modest energy support; fat metabolism assistance when combined with caloric deficit and exercise. No meaningful standalone fat loss.
Monitor: Monitor injection sites for nodules. If fishy body odor develops, reduce frequency to 2x/week maximum.
Remove the Lipo-C vial from the refrigerator 10 to 15 minutes before injection. Let it reach room temperature. Check for clarity; if you see white particles, gently roll the vial between your palms until they dissolve.
Clean the vial stopper with an alcohol swab and let it air dry for 10 seconds.
Using a 1 mL syringe with a 25 to 27 gauge needle (1 to 1.5 inch for intramuscular, 5/8 inch for subcutaneous), draw the plunger to 1 mL of air and inject the air into the vial. This equalizes pressure.
Pull the syringe to the 1.0 mL mark, which equals the complete per-injection dose containing approximately 50 mg choline, 50 mg L-carnitine, 50 mg inositol, 15 mg methionine, 15 mg thiamine, and 5 mg dexpanthenol.
Push the plunger gently until a small drop appears at the needle tip.
For intramuscular: inject into the vastus lateralis (outer quad), gluteus, or deltoid at a 90-degree angle. For subcutaneous: pinch skin at the abdomen or outer thigh and insert at a 45-degree angle.
Withdraw the needle and apply gentle pressure with a cotton ball.
Use a minimum of 7 distinct sites if injecting daily. Mark your rotation to avoid repeating.
The B-vitamin energy effect peaks 2 to 4 hours post-injection. Return the vial to the refrigerator immediately after use.
No dose difference; 1 mL per injection regardless of route
Quad (vastus lateralis) preferred in community due to fewest adverse reactions. Glute and deltoid also used clinically. 25–27g, 1–1.5 inch needle. Minimal injection site reactions at this route.
Same dose (1 mL); absorption slightly slower than IM but bioavailability near 100% for either route
SC abdomen is common but carries documented higher risk of injection site burning and nodule formation vs IM. 5/8 inch, 25–27g needle. Strictly limit to 1 mL per site injection. Community increasingly disfavors SC abdomen for Lipo-C specifically.
Most common clinical stack: Lipo-C provides energy support and liver lipotropic coverage during GLP-1-induced caloric restriction. Weight loss telehealth clinics (Defy Medical, Empower) routinely prescribe together.
1 mL Lipo-C 2–3x/week on non-semaglutide days
Same rationale as semaglutide stack: Lipo-C used as metabolic support adjunct. Fella Health clinical review confirms this as the most common Lipo-C combination seen clinically.
1 mL Lipo-C 2x/week; inject on non-tirzepatide days
Complementary fat mobilization mechanisms: AOD targets GH fragment lipolytic pathway; Lipo-C provides lipotropic/mitochondrial support. Common in clinic weight loss stacks.
Both injected as prescribed by clinic; AOD 250–300 mcg SC daily separate from Lipo-C IM injection
Same GLP-1 adjunct rationale as semaglutide. Less common since semaglutide displaced liraglutide in weight management, but still prescribed in some clinic programs.
1 mL Lipo-C 2x/week alongside daily liraglutide
Methionine in Lipo-C is a precursor to S-adenosylmethionine (SAMe), which donates methyl groups in serotonin synthesis. Combined with serotonergic drugs, there is a theoretical serotonin syndrome risk, particularly with MAOIs. This interaction is absent from current peptides.ts drug interactions field.
Methionine competes with levodopa for neutral amino acid transport across the blood-brain barrier, potentially reducing CNS levodopa bioavailability and worsening Parkinson's disease control.
Methionine affects homocysteine metabolism and potentially clotting parameters. Monitor INR closely if combining.
Pricing updated 2026-04-09
The most clinically relevant safety concern with Lipo-C is hepatotoxicity in individuals with pre-existing liver disease. Methionine excess leads to hypermethioninemia, which is directly hepatotoxic. Severe liver disease and bile duct obstruction are contraindications, not precautions. That distinction matters because Lipo-C is sometimes marketed for "liver support," which could mislead someone with actual hepatic pathology into thinking it would help. Fishy body odor is the side effect that gets the most attention in community discussions. Choline is converted by gut bacteria into trimethylamine (TMA). TMA gets excreted through sweat, breath, and urine. The smell can persist 24 hours post-injection at daily dosing frequency. Individuals with impaired FMO3 enzyme activity (the enzyme that converts TMA to odorless TMAO) are especially susceptible; people with diagnosed trimethylaminuria (TMAU) should avoid Lipo-C entirely. Reducing injection frequency to twice weekly and injecting in the morning are the two most effective mitigations the community has identified. Injection site reactions are common (>10% of users reporting). Mild pain, redness, and swelling at the injection site are standard for any injectable formulation. A 2021 case report documented something more concerning: localized skin inflammation and lipogranuloma-like nodules from repeated choline injections at the same site. Strict injection site rotation (minimum 7 distinct sites) is required, particularly at daily dosing frequency. Subcutaneous abdominal injection carries higher nodule risk than intramuscular routes per community reports. Nausea and GI upset occur occasionally, especially when stacking Lipo-C with GLP-1 agonists. The compound GI burden of semaglutide or tirzepatide plus Lipo-C can worsen nausea in susceptible individuals. Separating injection timing by several hours helps. Increased urination is expected as excess water-soluble B vitamins are cleared renally. This is physiologically normal and not a safety concern in healthy individuals. Active kidney disease changes this calculation; impaired renal clearance of water-soluble vitamins is listed as a contraindication. Methionine interacts with anticoagulants through homocysteine metabolism. Patients on warfarin should have INR monitored within 2 weeks of starting Lipo-C and monthly thereafter. L-carnitine may reduce the cellular effectiveness of thyroid hormones, which matters for patients on levothyroxine. And methionine, as a SAMe precursor, feeds into serotonin synthesis, creating a theoretical serotonin syndrome risk when combined with MAOIs. Rare allergic reactions (hives, swelling, difficulty breathing) have been reported. Stop immediately and seek emergency care for any signs of anaphylaxis. Pregnancy and breastfeeding safety has not been established. Assume contraindicated until data says otherwise.
Verify Lipo-C dosing and safety with a second opinion
Compounding pharmacy quality varies significantly. Two dominant formulations (Empower 4-ingredient and Hallandale "Bio Boost Plus" 10-ingredient including lidocaine, L-arginine, B6, B12) are pharmacologically distinct but both sold under the "Lipo-C" name. No FDA batch testing or efficacy review applies to 503A compounded products.
| Test | When | Target |
|---|---|---|
| Liver function panel (ALT, AST, bilirubin) | Baseline; repeat at 12 weeks if history of liver disease | ALT/AST within 2x upper limit of normal |
| INR (if on warfarin) | Within 2 weeks of starting Lipo-C; monthly thereafter | Therapeutic range per prescriber (typically 2.0–3.0 for AF; 2.5–3.5 for mechanical valves) |
| Body weight and waist circumference | Baseline; every 4 weeks | — |
| Injection site inspection | Each injection; formal assessment at weeks 4 and 8 | — |
Methionine excess can cause hypermethioninemia and hepatotoxicity in individuals with impaired liver function or bile duct obstruction. Relevant contraindication group.
Methionine affects homocysteine metabolism and may influence clotting parameters in anticoagulant-dependent patients.
Primary outcome assessment: distinguishes Lipo-C contribution from concurrent diet/GLP-1 effects.
2021 case report documented lipogranuloma-like nodules from repeated choline injections at same site. Strict rotation must be maintained.
Initial adjustment period. Some users report a mild increase in energy levels from the B-vitamin components. No significant body composition changes expected yet. Injection site tenderness may occur as the body adapts.
Gradual improvements in energy and exercise tolerance. When combined with a calorie deficit and regular exercise, early fat loss may become noticeable. Liver fat processing may improve based on the lipotropic effects of MIC.
Continued support for fat metabolism. Users following a structured diet and exercise plan may observe measurable changes in body composition. The L-Carnitine component supports ongoing fatty acid oxidation during exercise.
A short break of 2 weeks is typically recommended before resuming. Long-term use is generally considered safe given the nutrient-based formulation. Sustained results depend entirely on maintaining healthy lifestyle habits.
Days 1 through 7: Thiamine and dexpanthenol absorb rapidly after intramuscular or subcutaneous injection. B-vitamin cofactor replenishment starts within hours. The most consistently reported early effect is an energy boost within 2 to 4 hours of the first injection. Some users notice a warm sensation or mild flushing at the injection site. Injection site soreness and mild burning at subcutaneous sites are common. Fishy body odor from choline may appear from day one in susceptible individuals. No body composition changes are expected this early. Weeks 2 through 4: Choline and methionine begin supporting hepatic phosphatidylcholine synthesis and VLDL-mediated fat export from the liver. L-carnitine starts contributing to mitochondrial fatty acid oxidation, particularly during exercise. Users maintaining a caloric deficit and exercise program report improved exercise endurance and recovery. Sedentary users without a deficit report minimal response. Fishy odor becomes more consistent at 3x/week or daily dosing. Injection site nodule risk increases with repeated use at the same location. Weeks 4 through 8: L-carnitine data from the 2025 umbrella meta-analysis [1] shows clinically meaningful but modest weight reduction (effect size -1.11 kg) at 8 to 30 weeks with 150 to 4,000 mg/day oral dosing. The injectable route bypasses first-pass metabolism but equivalent fat loss data specific to intramuscular or subcutaneous delivery is not established. Users in structured programs report incremental improvement over diet alone. Users without a caloric deficit report minimal to no fat loss. Energy benefits persist. Formulation quality issues (crystallization, potency drift) may surface; site rotation discipline remains critical. Weeks 8 through 12: Component-level benefits are expected to sustain with continued use. No tolerance develops because these are nutrients, not receptor agonists. Most users who report benefit maintain it through the full 12 weeks. Some reduce to 2x/week maintenance after initial response. A two-week break before repeating the course is standard clinic protocol. No new side effects typically emerge at this stage, but cumulative injection site burden should be assessed.
Thiamine and dexpanthenol (provitamin B5) absorbed rapidly IM/SC; B-vitamin cofactor replenishment begins within hours. No body composition change expected.
Noticeable energy boost within 2–4 hours of first injection is the most consistently reported early effect. Some users report warm sensation or mild flushing at injection site.
Choline and methionine support hepatic phosphatidylcholine synthesis and VLDL-mediated fat export. L-carnitine begins supporting mitochondrial fatty acid oxidation, especially during exercise. No population-level fat loss expected without caloric deficit.
Improved exercise endurance and recovery reported by users maintaining caloric deficit and exercise program. Minimal response in sedentary users.
L-carnitine RCT data (PMID 40298161 umbrella meta-analysis) shows clinically significant but modest weight reduction (−1.11 kg ES) at 8–30 weeks with 150–4,000 mg/day oral. Injectable route bypasses first-pass but equivalent fat loss data specific to IM/SC route is not established.
Users in structured diet and exercise programs report incremental improvement over diet alone. Users without caloric deficit report minimal to no fat loss. Energy benefit persists.
Component-level benefits expected to be sustained with continued use. No tolerance development expected for nutrient-based compounds.
Most users who report benefit maintain it through 12 weeks. Some reduce to 2x/week maintenance after initial response. Two-week break typically observed before repeating course per clinic protocol.
Source: Estimated average across components. L-Carnitine plasma half-life ~4-6 hours; B vitamins ~2-6 hours. No single half-life applies to the blend.
Loading the interactive decay curve.
Lipo-C is not FDA-approved. It is a 503A compounded product, meaning it is mixed by licensed compounding pharmacies on a per-patient prescription basis. No FDA review of safety, efficacy, or manufacturing consistency applies to 503A compounds. The FDA has authority over compounding pharmacies but does not pre-approve individual formulations. Lipo-C requires a prescription in the United States. There is no legitimate non-prescription injectable Lipo-C product on the US market. Any source selling it without a prescription is operating outside the regulated framework. WADA status: individual components (L-carnitine, B vitamins, amino acids) are not currently prohibited by the World Anti-Doping Agency. Athletes should verify current status on the WADA prohibited list before use, as classifications change annually. Compounding pharmacy quality varies. Confirm your pharmacy holds a valid state 503A license and request a Certificate of Analysis (CoA) for your batch. Two pharmacologically distinct formulations are sold under the "Lipo-C" name. This content is for informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any injectable protocol.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
